Vaccine developed in Oxford criticised by FDA with efficacy rates and trials stalling official take-up
For a man presenting landmark results from trials of a vaccine that it is hoped will save the world from a devastating pandemic, Sir Menelas Pangalos did not look cheerful on Wednesday.
Pangalos, executive vice-president of biopharmaceuticals R&D at AstraZeneca, and his colleagues, are undoubtedly exhausted, having been working round the clock on the coronavirus vaccine with Oxford University since April. But they are now dealing with a sizeable new headache – the doubts of the US regulator.
